Neighbors describe searching for injured 18-year-old, watching tornado touch down in Henry County
NewsChopper 2 flew over Fresh Laurel Lane where an EF-2 tornado destroyed a home on Thursday afternoon.
[DOWNLOAD: Free WSB-TV News app for alerts as news breaks]
Malachi Chaney, 18, was thrown 300 feet from the house and severely injured. He remains in critical condition at Grady Memorial Hospital.
Channel 2's Tyisha Fernandes visited what was left of the home on Friday and spoke with neighbors who described the terrifying moments.
'It was just raining, there was no wind, just a steady rain, and I was standing in my kitchen, and I started hearing like 'ping, ping, ping,' and I was like, 'What is that?' And I pulled the sliding glass door back right here, and I see right over here a funnel touching the ground. I immediately ran in my closet, covered my head, and took cover, and just started praying, panicking, and I could hear things hitting the house. It was really loud," Courtney Bucio said.
RELATED STORIES:
'The Wire' actor says his son was 'thrown 300 feet' from their home in Henry County tornado
Tornado touches down in Henry County, 18-year-old critically injured
Tornado touches down in Henry County, crosses I-75
When the noises stopped, neighbors came outside and learned their neighbor Tray Chaney, an actor who played Malik 'Poot' Carr on 'The Wire,' and his 18-year-old son were in the home.
Neighbors say Malachi Chaney was upstairs playing video games when the tornado hit.
Fernandes took neighbors' concerns for their safety to the homebuilder, Century Communities. They say their homes are well-constructed. A spokesperson said that any home would have looked like that if it was directly hit by a tornado.
[SIGN UP: WSB-TV Daily Headlines Newsletter]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Cable detaches on Ohio amusement park ride
A cable on a ride at a popular Ohio amusement park detached while people were riding it on Sunday. [DOWNLOAD: Free WHIO-TV News app for alerts as news breaks] Cedar Point's Power Tower ride was closed on Monday after a cable on one of the ride's towers detached from the ride vehicle on Sunday evening, CBS affiliate WOIO-19 reported. TRENDING STORIES: Check your tickets! 3 winning Powerball tickets sold in Ohio 1 in custody after county-wide call for help issued in Montgomery County Man found in sewer drain after large search forces shelter-in-place in Montgomery County The safety system performed as designed, and the ride vehicle returned to the loading position, according to Cedar Point Spokesperson Tony Clark. None of the guests were injured, WOIO-19 reported. 'Safety is a top priority, and the ride will remain closed while we complete a thorough review and inspection of the ride,' Clark said. [SIGN UP: WHIO-TV Daily Headlines Newsletter] Solve the daily Crossword
Miami Herald
10 hours ago
- Miami Herald
MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
Manuscript accepted for publication in Frontiers in Pharmacology, "Oral Administration of Ketamir-2, a Novel Ketamine Analog, Attenuates Neuropathic Pain in Rodent Models via Selective NMDA Antagonism" details Ketamir-2's superior performance in two validated neuropathic pain models and supports advancement to Phase 2a clinical trials by year-end 2025. MIAMI, FL / ACCESS Newswire / August 12, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the acceptance of a second peer-reviewed manuscript describing its lead oral drug candidate, Ketamir-2, in Frontiers in Pharmacology. The newly accepted publication reports that Ketamir-2 outperformed ketamine, pregabalin, or gabapentin-depending on the comparator used-in restoring sensory function and reversing pain behaviors across two gold-standard rodent models of neuropathic pain. The findings build on MIRA's first publication characterizing Ketamir-2's clean pharmacology and favorable safety profile and align with the Company's plan to initiate a Phase 2a trial in neuropathic pain by year-end 2025. Market Opportunity Neuropathic pain represents a significant and underserved market across North America. Epidemiology suggests approximately 7-10% of the population experiences neuropathic pain; in North America, this equates to approximately 36-51 million people across the U.S., Canada, and Mexico. According to Precedence Research, the global neuropathic pain market is valued at approximately $7.97 billion in 2024 and is projected to reach $16.79 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.73%. North America accounts for a significant share of this market, representing an estimated $3.7-3.9 billion annually today. The U.S. neuropathic pain market is estimated at $2.79 billion in 2024 and is projected to reach $5.92 billion by 2034, growing at a CAGR of 7.80% over the same period. Growth is expected to be driven by rising prevalence of diabetes, cancer survivorship, and aging-related nerve damage, underscoring the large and expanding commercial potential for novel treatments such as Ketamir-2. Ketamir-2's differentiated mechanism, oral bioavailability, and superior performance in gold-standard preclinical models position it as a potential next-generation, non-opioid treatment option in this multi-billion-dollar and rapidly growing market. Key Findings from the Publication Chung Model (sciatic nerve ligation in rats)Male rats: Ketamir-2 restored sensory thresholds toward baseline, while ketamine-tested as the comparator-showed no measurable rats: Ketamir-2 outperformed both pregabalin and gabapentin, delivering greater and more consistent restoration of normal sensory (PTX)-Induced Neuropathy in MiceGabapentin was the sole comparator in this chemotherapy-induced neuropathy model. Ketamir-2 produced more complete normalization of pain sensitivity in both male and female cohorts, while gabapentin provided only partial or inconsistent Across Genders and SpeciesDespite differences in baseline pain sensitivity between male and female animals, Ketamir-2 demonstrated clear and significant therapeutic benefit in every cohort tested. Mechanistic Differentiation Ketamir-2 is a new molecular entity that selectively binds to the PCP site of the NMDA receptor with low affinity and shows no significant interaction with over 40 other receptor systems, including serotonin, dopamine, and opioid receptors. This combination of selectivity, oral bioavailability, and demonstrated efficacy in gold-standard models suggests the potential for a differentiated, next-generation therapeutic option in neuropathic pain. "The acceptance of this second peer-reviewed publication is another important milestone for our Ketamir-2 program," said Erez Aminov, CEO of MIRA. "The data clearly demonstrate superior and more consistent pain relief compared to leading neuropathic pain drugs, within the specific models tested. This provides additional confidence as we advance Ketamir-2 toward Phase 2a clinical evaluation and continue to explore its potential in broader CNS applications." "The robust reversal of pain sensitivity observed in these well-validated preclinical models-whether compared to ketamine, pregabalin, or gabapentin-further supports Ketamir-2's potential as a differentiated, orally administered treatment for neuropathic pain," added Dr. Itzchak Angel, Chief Scientific Advisor. "Given the limited number of effective oral treatments for this indication, Ketamir-2's profile is especially compelling." Clinical Development Update Phase 1 Trial Progressing: The ongoing Phase 1 trial of Ketamir-2 in Israel is on schedule, with no safety concerns reported to date and the single ascending dose portion nearing 2a by Year-End: MIRA plans to submit a Phase 2a clinical trial protocol to the U.S. Food and Drug Administration (FDA) in Q4 2025 as an advanced development version to its active IND, with the goal of initiating the study in neuropathic pain by Beyond Neuropathic Pain: With its clean pharmacology and oral bioavailability, Ketamir-2 is also being explored for potential applications in depression, anxiety, post-traumatic stress disorder (PTSD), and as a topical formulation for localized pain conditions. The full publication will be available upon release at: About MIRA Pharmaceuticals, Inc. MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking Statements This press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact:Helga Moyainfo@ 432-9792 SOURCE: MIRA Pharmaceuticals
Yahoo
12 hours ago
- Yahoo
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected in all three indications this year with first-in-class potential in NT2 and IH ORX142 Phase 1 clinical trial for the treatment of select neurological and neurodegenerative disorders underway with data in acutely sleep-deprived healthy volunteers expected this year ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results and business highlights for the second quarter ended June 30, 2025. 'As clinical validation of the orexin agonist class continues to grow, we believe Centessa is well positioned with a novel potential best-in-class OX2R agonist pipeline aimed at redefining the standard of care. This includes not only restoring normal wakefulness to meet the real-world needs of individuals with sleep-wake disorders, but also potentially addressing comorbidities such as excessive daytime sleepiness, impaired attention, cognitive deficits and fatigue across a range of neurological, neurodegenerative and neuropsychiatric conditions where there is unmet need,' said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. Dr. Saha continued, 'ORX750, our most advanced OX2R agonist drug candidate, is progressing in an adaptive Phase 2a study that incorporates real-time drug development strategies aimed at optimizing dosing and best positioning ORX750 for planned registrational studies. This innovative approach continues to build our confidence in ORX750's potential to be a best-in-class OX2R agonist for the treatment of NT1, NT2 and IH, and potentially the first OX2R agonist to treat NT2 and IH. Our top priority remains the successful execution of the Phase 2a study, and we look forward to sharing data for ORX750 in all three indications this year.' 'In parallel, we recently initiated clinical development of ORX142, our second OX2R agonist drug candidate, with data in acutely sleep-deprived healthy volunteers also expected this year. With two programs advancing toward key clinical milestones and a broad pipeline of potentially transformative orexin therapies, we believe Centessa is positioned to become a long-term leader in the orexin space,' concluded Dr. Saha. Recent Highlights Following clearance of the Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) in June 2025, the Company initiated a Phase 1 first-in-human clinical trial of ORX142, with data in acutely sleep-deprived healthy volunteers expected this year. In April 2025, additional data from the Phase 1 study of ORX750 were presented in a poster session at the American Academy of Neurology (AAN) Annual Meeting. Along with previously disclosed Phase 1 data, the poster highlighted time-course curves for both the Maintenance of Wakefulness Test (MWT) and the Karolinska Sleepiness Scale (KSS) from the 5.0 mg dose cohort. At this dose, sustained effects were observed across the full 8-hour post-dose observation period, with mean sleep latency exceeding 30 minutes on the MWT and improvements in KSS scores compared to placebo. An abstract highlighting the adaptive design of the Company's Phase 2a CRYSTAL-1 study for ORX750, including an open-label long-term extension (LTE), has been accepted as a poster presentation at the World Sleep 2025 Congress being held on September 5–10, 2025, in Singapore. The abstract, Development of a Novel, Oral Orexin Receptor 2 Agonist, ORX750 for Treatment of Patients with Narcolepsy (type 1 and 2) and Idiopathic Hypersomnia, is available on the conference website. A copy of the poster will be available on the Centessa website at at the time of the poster presentation. OX2R Agonist Pipeline and Anticipated Upcoming Milestones ORX750: The Phase 2a CRYSTAL-1 study is ongoing with data in NT1, NT2 and IH expected in 2025. ORX142: The Phase 1 first-in-human study of ORX142 is ongoing with data in acutely sleep-deprived healthy volunteers expected in 2025. ORX489: Currently in IND-enabling studies. Second Quarter 2025 Financial Results Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments totaled $404.1 million as of June 30, 2025. The Company expects its cash, cash equivalents and investments as of June 30, 2025 will fund operations into mid-2027. Research & Development (R&D) Expenses: R&D expenses were $42.7 million for the second quarter ended June 30, 2025, compared to $32.8 million for the second quarter ended June 30, 2024. General & Administrative (G&A) Expenses: G&A expenses were $11.9 million for the second quarter ended June 30, 2025, compared to $11.2 million for the second quarter ended June 30, 2024. Net Loss: Net loss was $50.3 million for the second quarter ended June 30, 2025, compared to $43.8 million for the second quarter ended June 30, 2024. About Centessa's Orexin Receptor 2 (OX2R) Agonist Program Orexin is a neuropeptide that regulates the sleep-wake cycle, leading to arousal and promoting wakefulness. Targeting the orexin pathway with novel orexin receptor 2 (OX2R) agonists represents a potential promising approach to address excessive daytime sleepiness (EDS), impaired attention, cognitive deficits and fatigue associated with a broad range of neurological, neurodegenerative and neuropsychiatric disorders. Centessa is developing a pipeline of potential best-in-class OX2R agonists, including ORX750 for the treatment of sleep-wake disorders including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), ORX142 for the treatment of select neurological and neurodegenerative disorders, and ORX489 for the treatment of neuropsychiatric disorders. ORX750 is being evaluated in the Phase 2a CRYSTAL-1 study. For more information, visit ORX750, ORX142 and ORX489 are investigational candidates and have not been approved by the FDA or any other regulatory authority. About Centessa Pharmaceuticals Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of EDS, impaired attention, cognitive deficits and fatigue across neurological, neurodegenerative and neuropsychiatric disorders. For more information, visit which does not form part of this release. Forward Looking Statements This press release contains forward-looking statements. These statements may be identified by words such as 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'ongoing,' 'aim,' 'seek,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including statements related to the Company's ability to discover and develop transformational medicines for patients; its expectations for executing on the Company's pipeline; its expectations on its anticipated cash runway; the timing of commencement of new studies or clinical trials or clinical and preclinical data related to ORX750, ORX142, ORX489 and other OX2R agonist molecules; its ability to identify, screen, recruit and maintain a sufficient number of or any subjects in its existing and anticipated studies or clinical trials of ORX750, ORX142, ORX489 and other OX2R agonist molecules; its expectations on executing its research and clinical development plans and the timing thereof; its expectations as to the potential results and impact of each of its clinical programs and trials; the Company's ability to differentiate ORX750, ORX142, ORX489 and other OX2R agonist molecules from other treatment options, including those being developed by competitors; the development, design and therapeutic potential of ORX750, ORX142, ORX489 and other OX2R agonist molecules, including the potential for ORX750 to be a best-in-class OX2R agonist for the treatment of NT1, NT2 and IH, and potentially the first OX2R agonist to treat NT2 and IH; and regulatory matters, including the timing and likelihood of success of obtaining regulatory clearance or authorizations to initiate or continue clinical trials. Any forward-looking statements in this press release are based on our current expectations, estimates, assumptions and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the safety and tolerability profile of our product candidates; our ability to identify, screen and recruit a sufficient number of or any subjects in our existing and anticipated new studies or clinical trials of ORX750, ORX142, ORX489 or within anticipated timelines; our expectations relating to the clinical trials of ORX750 and ORX142, including the predicted timing of enrollment, the predicted efficacious doses of ORX750 and ORX142 and our ability to successfully conduct our clinical development of ORX750 and ORX142, our ability to protect and maintain our intellectual property position; business (including commercial viability), regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company; risks inherent in developing product candidates and technologies; future results from our ongoing and planned clinical trials; our ability to obtain adequate financing, including through our financing facility with Oxford Finance, to fund our planned clinical trials and other expenses; trends in the industry; the legal and regulatory framework for the industry, including the receipt and maintenance of clearances to conduct or continue clinical testing; our operating costs and use of cash, including cash runway, cost of development activities and conducting clinical trials, future expenditures risks; the risk that any one or more of our product candidates will not be successfully developed and/or commercialized; the risk that the historical results of preclinical studies or clinical studies will not be predictive of future results in ongoing or future studies; economic risks to the United States and United Kingdom banking systems; and geo-political risks such as the Russia-Ukraine war, the Middle East conflicts or trade wars and impact of the imposition of tariffs. These and other risks concerning our programs and operations are described in additional detail in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and our other reports, which are on file with the U.S. Securities and Exchange Commission (SEC). We explicitly disclaim any obligation to update any forward-looking statements except to the extent required by law. Contact: Kristen K. Sheppard, Esq. SVP of Investor Relations investors@ Centessa Pharmaceuticals plcConsolidated Statements of Operations and Comprehensive Loss(unaudited)(amounts in thousands except share and per share data) Three Months EndedJune 30, 2025 Three Months EndedJune 30, 2024 Six Months EndedJune 30, 2025 Six Months EndedJune 30, 2024 License and other revenue $ — $ — $ 15,000 $ — Operating expenses: Research and development 42,741 32,815 76,184 55,467 General and administrative 11,912 11,165 24,246 24,603 Loss from operations (54,653 ) (43,980 ) (85,430 ) (80,070 ) Interest and investment income 4,380 3,240 12,270 5,831 Interest expense (2,884 ) (2,525 ) (5,761 ) (5,054 ) Other non-operating income (expense), net 3,592 154 4,618 (1,383 ) Loss before income taxes (49,565 ) (43,111 ) (74,303 ) (80,676 ) Income tax expense 778 705 2,175 1,186 Net loss (50,343 ) (43,816 ) (76,478 ) (81,862 ) Other comprehensive (loss) income: Foreign currency translation adjustment (479 ) (61 ) 164 (86 ) Unrealized (loss) gain on available for sale marketable securities, net of reclassification adjustment and tax (5 ) 33 (2,786 ) 188 Other comprehensive (loss) income (484 ) (28 ) (2,622 ) 102 Total comprehensive loss $ (50,827 ) $ (43,844 ) $ (79,100 ) $ (81,760 ) Net loss per ordinary share - basic and diluted $ (0.38 ) $ (0.40 ) $ (0.57 ) $ (0.78 ) Weighted average ordinary shares outstanding - basic and diluted 133,677,405 109,489,184 133,354,373 104,688,452 Centessa Pharmaceuticals plcCondensed Consolidated Balance Sheets(unaudited)(amounts in thousands) June 30, 2025 December 31, 2024 Total assets: Cash and cash equivalents $ 44,242 $ 383,221 Investments in marketable securities 359,888 98,956 Other assets 87,997 94,621 Total assets $ 492,127 $ 576,798 Total liabilities Other liabilities $ 37,663 $ 66,313 Long term debt 109,545 108,940 Total liabilities 147,208 175,253 Total shareholders' equity 344,919 401,545 Total liabilities and shareholders' equity $ 492,127 $ 576,798 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
